Illumina (company)

Infobox Company
name = Illumina

type = Public (nasdaq|ILMN)
genre =
foundation = 1998
founder =
location_city = San Diego, California
location_country = U.S.
location =
locations =
area_served =
key_people =
industry =
products =
services =
revenue = $140.18 million (Q2 2008)
operating_income =
net_income =
owner =
num_employees =
parent =
divisions =
subsid =
slogan =
homepage = http://www.illumina.com/
footnotes =
intl =

Illumina, Inc. (nasdaq|ILMN), incorporated in April 1998, develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function. Using its technologies, the Company provides a line of products and services that serve the sequencing, genotyping and gene expression markets. Customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations and biotechnology companies. Its tools provide researchers with the capability to perform genetic tests needed to extract medical information from advances in genomics and proteomics.

History

Illumina was founded in April of 1998 by David Walt, Ph.D., CW Group (Larry Bock), John Stuelpnagel, D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.D. While working with CW Group, a venture capital firm, Larry and John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Headquartered in San Diego, California, Illumina completed its initial public offering in July, 2000.

Illumina began offering SNP genotyping services in 2001 and launched its first system, the Illumina BeadLab, in 2002, using GoldenGate Genotyping technology. Illumina currently offers microarray-based products and services for an expanding range of genetic analysis sequencing, including SNP genotyping, gene expression, and protein analysis. Illumina’s technologies are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.

On January 26, 2007, the Company completed the acquisition of Solexa, Inc. Solexa develops and commercializes genetic analysis technologies used to perform a range of analyzes, including whole genome resequencing, gene expression analysis and small ribonucleic acid (RNA) analysis.